Billiontoone (NASDAQ:BLLN) Insider Sells $1,063,173.54 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Nancy Joann Johnson sold 10,582 shares of Billiontoone stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $100.47, for a total transaction of $1,063,173.54. Following the completion of the transaction, the insider directly owned 21,900 shares in the company, valued at $2,200,293. This represents a 32.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nancy Joann Johnson also recently made the following trade(s):

• On Monday, June 8th, Nancy Joann Johnson sold 3,418 shares of Billiontoone stock. The stock was sold at an average price of $99.28, for a total transaction of $339,339.04.

Billiontoone Stock Performance

NASDAQ BLLN traded down $3.13 on Wednesday, hitting $99.26. The stock had a trading volume of 1,040,614 shares, compared to its average volume of 694,048. The business’s fifty day moving average price is $87.26 and its 200 day moving average price is $88.18. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58. Billiontoone, Inc. has a 52-week low of $61.96 and a 52-week high of $138.70.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.33. The firm had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $95.81 million. During the same period in the prior year, the firm posted ($0.39) earnings per share. Billiontoone’s revenue for the quarter was up 83.8% compared to the same quarter last year. Sell-side analysts anticipate that Billiontoone, Inc. will post 0.93 EPS for the current fiscal year.

Hedge Funds Weigh In On Billiontoone

Several hedge funds have recently made changes to their positions in BLLN. Adams Street Partners LLC acquired a new position in shares of Billiontoone in the 4th quarter valued at $140,063,000. Baillie Gifford & Co. acquired a new position in shares of Billiontoone in the 4th quarter valued at $103,786,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Billiontoone in the 4th quarter valued at $39,717,000. JPMorgan Chase & Co. acquired a new position in shares of Billiontoone in the 4th quarter valued at $32,078,000. Finally, Wasatch Advisors LP acquired a new position in shares of Billiontoone in the 1st quarter valued at $29,179,000.

Analyst Ratings Changes

Several research firms have issued reports on BLLN. Weiss Ratings lowered shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 5th. JPMorgan Chase & Co. lifted their price target on shares of Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Wall Street Zen raised Billiontoone from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Wells Fargo & Company cut their target price on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 5th. Finally, BTIG Research cut their target price on Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $125.29.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.